Gonadorelin

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Gonadorelin is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1982. DrugCentral lists 3 molecular targets, including Lhcgr, Gnrhr and GNRHR. Recorded indications include Amenorrhea and Diagnostic Test for Gonadotropin Deficiency.

• Approval status: ofm (first approved 1982 by the FDA).
• Molecular targets: Lhcgr, Gnrhr and GNRHR (3 listed in DrugCentral).
• Indications: Amenorrhea and Diagnostic Test for Gonadotropin Deficiency.
• ATC code: H01CA01 (Gonadotropin-releasing hormones).
• Molecular formula: C55H75N17O13; molecular weight 1182.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Amenorrhea
• Diagnostic Test for Gonadotropin Deficiency

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Lutropin-choriogonadotropic hormone receptor	Lhcgr	unknown	Ki 8.90
Gonadotropin-releasing hormone receptor	Gnrhr	unknown	IC50 8.70
Gonadotropin-releasing hormone receptor	GNRHR	agonist	IC50 8.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1982-09-30	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
H01CA01	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › HYPOTHALAMIC HORMONES › Gonadotropin-releasing hormones
V04CM01	VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for fertility disturbances

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Metastases to bone	202.0
Neutropenia	197.7
Ovarian hyperstimulation syndrome	133.3
Malignant neoplasm progression	115.2
Carcinoembryonic antigen increased	78.7
Carbohydrate antigen 15-3 increased	61.5
Metastases to lymph nodes	55.9
Hot flush	54.9
Alanine aminotransferase increased	54.7
Bone lesion	51.6
Metastases to liver	51.3
Radiation fibrosis - lung	50.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Gonadorelin is on its molecule page.

• Molecular formula: C₅₅H₇₅N₁₇O₁₃
• Molecular weight: 1182.31 g/mol
• CAS number: 33515-09-2
• InChIKey: XLXSAKCOAKORKW-AQJXLSMYSA-N
• PubChem CID: 638793

CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Gonadorelin used for?

DrugCentral lists the following indications for Gonadorelin: Amenorrhea and Diagnostic Test for Gonadotropin Deficiency.

How does Gonadorelin work?

Its molecular targets in DrugCentral include Lhcgr, Gnrhr and GNRHR (agonist).

When was Gonadorelin first approved?

Gonadorelin was first approved by the FDA in 1982.

What is the chemical formula of Gonadorelin?

Gonadorelin has the molecular formula C55H75N17O13 and a molecular weight of 1182.31 g/mol.

Sources

• DrugCentral drug card 2958 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1007 — compound record and bioactivity
• PubChem CID 638793 — chemical identifiers
• DrugBank DB00644 — drug record
• FDA UNII 9O7312W37G — substance identity
• DailyMed: FDA labels for Gonadorelin — current prescribing information (label search)
• UniProt P30968 (GNRHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.